Hayward, California-based Pulse Biosciences also expanded the role of Dr. David Kenigsberg to full-time chief medical officer (CMO).
The pulsed field ablation (PFA) technology developer says the appointments enhance its strategic alignment. It hopes to prioritize and accelerate the development and future commercialization of its nPulse PFA system.
As COO, Teplitsky’s responsibilities include overseeing clinical, regulatory, quality and commercial functions. She brings 20 years of experience in medtech. Most recently, Teplitsky served as CEO of Artedrone, leading the development of autonomous robotic technology for treating stroke.
Before Artedrone, Teplitsky held senior marketing and leadership roles at Abbott and St. Jude Medical. Her experience there included contributing to development, clinical validation and global commercialization efforts for cardiovascular and EP therapies. She also served as president of robotics, technology and data solutions at Zimmer Biomet.
Commentary from Pulse Biosciences officials
Paul LaViolette, co-chair and CEO of Pulse Biosciences, said:
“We are thrilled to welcome Liane to Pulse at such a consequential moment in the company’s development. She brings a wealth of relevant experience and a remarkable track record of building and scaling medtech businesses. Her operational and leadership experience will be instrumental in accelerating our strategic priorities with emphasis on the cardiac catheter development program. Together with Dr. Kenigsberg’s expanded commitment to our clinical strategy, we have expanded the depth and capability of our executive team and are now optimally positioned to execute on our clinical and regulatory objectives.”
Teplitsky added:
“What drew me to Pulse was the science; nanosecond PFA is a differentiated technology with the potential to meaningfully advance how atrial fibrillation is treated and patients respond. The clinical foundation is strong, the team is exceptional, and the company is at an inflection point where focused execution can make a real difference. I am eager to contribute and look forward to working alongside the Pulse team to deliver on that potential for patients.”
